Multinational pharmaceutical company AstraZeneca says it has found no evidence that a novel coronavirus infection vaccine developed with Oxford University in the UK increases the risk of developing blood clots.
AstraZeneca spokesman said, “The analysis of more than 10 million data showed no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in a particular age group, gender, manufacturing unit, or country,” the AFP news agency said.
“In fact, the size of this type of outbreak observed among vaccinators is much smaller than expected in the general population,” the spokesperson added.
Recently, some European countries have been vaccinated against AstraZeneca and there have been reports of blood clots, but their responses are different.
In Austria, the production unit was’ABV5300′ and in Italy, the production unit was temporarily stopped because a case of blood clotting was reported after the vaccine was vaccinated with AstraZeneca.
Bulgaria, Denmark, Norway and Iceland temporarily stopped vaccination against AstraZeneca as a precautionary measure in case of an unforeseen event.
Unlike these countries, the World Health Organization (WHO) and the European Medicines Agency (EMA) have declared that the AstraZeneca vaccine has no safety issues.
The UK, Sweden, France, Spain, and the Netherlands are continuing the AstraZeneca vaccination in line with the recommendations of WHO and EMA.
The French Agency for Health and Product Safety (ANSM) announced that there was only one case in France that reported blood clotting after receiving the AstraZeneca vaccine, and that a causal relationship with vaccination was not confirmed.
The Paulerrich Institute (PEI), which is responsible for vaccine approval in Germany, found no indication that AstraZeneca vaccination caused blood clot-related disorders.